Neovascular Glaucoma: A Historical Perspective on Modulating Angiogenesis

REFERENCES

• Sivak-Callcott J A, O'Day D M, Gass J DM, Tsai J C. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology 2001; 108: 1767–1776
   PubMed Web of Science ®Google Scholar
• Bushmann I, Schaper W. Arteriogenesis vs. angiogenesis: Two mechanisms of vessel growth. News Physiol Sci 1999; 14: 121–125
   Google Scholar
• System of Ophthalmology, Vol XI: Diseases of the Lens and Vitreous, Glaucoma and Hypotony, S Duke-Elder. C. V. Mosby, St Louis 1969, chapter 9
   Google Scholar
• Cairns J E. Rationale for therapy in neovascular glaucoma. Trans Ophthalmol Soc U K 1981; 184–185
   Google Scholar
• Michaelson I C. The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc U K 1948; 68: 137–180
   Google Scholar
• Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182–1186
   PubMed Web of Science ®Google Scholar
• Brown G C, Magargal L E, Schachat A, Shah H. Neovascular glaucoma. Etiologic considerations. Ophthalmology 1984; 91: 115–120
   Google Scholar
• Fanous M M. Neovascular Glaucoma. Albert and Jakobiec, Boston, MA 2009, Chapter 225
   Google Scholar
• Hayreh S S. Neovascular glaucoma. Progress in Retinal and Eye Research 2007; 26: 470–485
   PubMed Web of Science ®Google Scholar
• Aiello L P, Avery R L, Arrigg P G, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480–1487
   PubMed Web of Science ®Google Scholar
• Adamis A P, Miller J W, Bernal M T, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445–450
   PubMed Web of Science ®Google Scholar
• Adamis A P, Miller J W, O'Reilly M, et al. Vascular permeability factor (vascular endothelial growth factor) is produced in the retina and elevated levels are present in the aqueous humor of eyes with iris neovascularization. Invest Ophthalmol Vis Sci 1993; 34: 1440, Abstract
   Web of Science ®Google Scholar
• Casey R, Li W W. Factors controlling ocular angiogenesis. Am J Ophthalmol 1997; 124: 521–529
   PubMed Web of Science ®Google Scholar
• Chen K H, Wu C C, Roy S, et al. Increased interleukin-6 in aqueous humor of neovacular glaucoma. Invest Ophthalmol Vis Sci 1999; 40: 2627–2632
   PubMed Web of Science ®Google Scholar
• Browning D J, Scott A Q, Peterson C B, et al. The risk of missing angle neovascularization by omitting screening gonioscopy in acute central retinal vein occlusion. Ophthalmology 1998; 105: 776–784
   Web of Science ®Google Scholar
• Ohnishi Y, Ishibashi T, Sagawa T. Fluorescein gonioangiography in diabetic neovascularization. Graefes Arch Clin Exp Ophthalmol 1994; 232: 199–204
   Google Scholar
• John T, Sassani J W, Eagle R C, Jr. The myofibroblastic component of rubeosis iridis. Ophthalmology 1983; 90: 721–728
   Google Scholar
• Aiello L M, Wand M, Liang G. Neovascular glaucoma and vitreous hemorrhage after cataract surgery in patients with diabetes mellitus. Ophthalmology 1983; 90: 814–820
   PubMed Web of Science ®Google Scholar
• Magargal L E, Brown G C, Augsburger J J, Donoso L A. Efficacy of panretinal photocoagulation in preventing neovascular glaucoma following ischemic central retinal vein obstruction. Ophthalmology 1982; 89: 780–784
   PubMedGoogle Scholar
• Pavan P R, Folk J C, Weingist T A, et al. Diabetic rubeosis and panretinal photocoagulation. A prospective, controlled, masked trial using iris fluorescein angiography. Arch Ophthlmol 1983; 01: 882–884
   Google Scholar
• Wand M, Dueker D K, Aiello L M, Grant W M. Effects of argon laser photocoagulation on rubeosis iridis, angle neovascularization and neovascular glauoma. Am J Ophthalmol 1978; 86: 332–339
   PubMed Web of Science ®Google Scholar
• Little H L, Rosenthal A R, Dellaporta A, Jacobson D R. The effect of panretinal photocoagulation on rubeosis iridis. Am J Ophthamol 1976; 81: 804–809
   PubMedGoogle Scholar
• Baseline and early natural history report. The Central Vein Occlusion Study. Central Vein Occlusion Study Group. Arch Ophthalmol 1993; 11: 1087–1095
   Google Scholar
• Allen R C, Bellows A R, Hutchinson B T, Murphy S D. Filtration surgery in the treatment of neovascular glaucoma. Ophthalmology 1982; 89: 1181–1187
   PubMed Web of Science ®Google Scholar
• Tsai J C, Feuer W J, Parrish R K, II, Grajewski A L. 5-Fluorouracil filtering surgery and neovascular glaucoma. Long-term follow-up of the original pilot study. Ophthalmology 1995; 102: 887–892
   PubMedGoogle Scholar
• Ruderman J M, Welch D B, Smith M F, Shoch D E. A randomized study of 5-Fluorouracil and filtration surgery. Am J Ophthalmol 1987; 104: 218–224
   PubMedGoogle Scholar
• Katz G J, Higginbotham E J, Lichter P R, et al. Mitomycin C versus 5-Fluorouracil in high-risk glaucoma filtering surgery. Extended follow-up. Ophthalmology 1995; 102: 1263–1269
   PubMed Web of Science ®Google Scholar
• Sidoti P A, Dunphy T R, Baerveldt G, et al. Experience with the Baerveldt glaucoma implant in treating neovascular glaucoma. Ophthalmology 1995; 102: 1107–1118
   PubMedGoogle Scholar
• Mermoud A, Salmon J F, Aexander P, et al. Molteno tube implantation for neovascular glaucoma. Long-term results and factors influencing the outcome. Ophthalmology 1993; 100: 897–902
   PubMedGoogle Scholar
• Krupin T, Kauffman P, Mandell A I, et al. Long-term results of valve implants in filtering surgery for eyes with neovascular glaucoma. Am J Ophthalmol 1983; 95: 775–782
   PubMed Web of Science ®Google Scholar
• Scott I U, Alexandrakis G, Flynn H W, Jr, et al. Combined pars plana vitrectomy and glaucoma drainage implant placement for refractory glaucoma. Am J Ophthamol 2000; 129: 334–341
   PubMed Web of Science ®Google Scholar
• Luttrull J K, Avery R L. Pars plana implant and vitrectomy for treatment of neovascular glaucoma. Retina 1995; 15: 379–387
   PubMedGoogle Scholar
• Avery R L, Pearlman J, Pieramici D J, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthamology 2006; 113: 1695–1705
   PubMed Web of Science ®Google Scholar
• Wakabayashi T, Oshima Y, Sakaguchi H, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008; 115: 1571–1580
   PubMed Web of Science ®Google Scholar
• Beutel J, Peters S, Luke M, et al. Bevacizumab as adjuvant for neovascular glaucoma. Acta Ophthalmologica 2008; 1–7
   Google Scholar
• Davidorf F H, Mouser J G, Derick R J. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina 2006; 26: 354–356
   PubMed Web of Science ®Google Scholar
• Andreoli C M, Miller J W. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 2007; 18: 502–508
   PubMed Web of Science ®Google Scholar
• Aiello L M, Beetham W P, Balodimos M C, . Ruby laser photocoagulation and treatment of diabetic proliferating retinopathy. Symposium on the Treatment of Diabetic Retinopathy, M F Goldberg, S L Fine, et al. U. S. Public Health Service, Washington, DC 1969; 437, 1890
   Google Scholar